SNDX ▲ +1.4% - Syndax Pharmaceuticals, Inc.
$SNDX - Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
04-NOV-2026 09:00 AM ET
Share this post
More filings for $SNDX
SNDX ▲ +1.4% - Syndax Pharmaceuticals, Inc.Nov 4, 2026SNDX ▼ -6.1% - Syndax Pharmaceuticals, Inc.Nov 2, 2026SNDX ▼ -6.1% - Syndax Pharmaceuticals, Inc.Nov 2, 2026SNDX ▼ -0.7% - Syndax Pharmaceuticals, Inc.Oct 30, 2026SNDX ▼ -0.4% - Syndax Pharmaceuticals, Inc.Oct 30, 2026SNDX ▲ +0.1% - Syndax Pharmaceuticals, Inc.Oct 26, 2026
View full $SNDX filing history →💬 Comments
Loading comments…
Leave a comment